Focused On-demand Library for Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O60231

UPID:

DHX16_HUMAN

Alternative names:

ATP-dependent RNA helicase #3; DEAH-box protein 16

Alternative UPACC:

O60231; O60322; Q5JP45; Q969X7; Q96QC1

Background:

Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16, also known as ATP-dependent RNA helicase #3 and DEAH-box protein 16, plays a crucial role in pre-mRNA splicing as part of the spliceosome. It is involved in the splicing of U12-type introns and acts as a pattern recognition receptor in the innate antiviral response, enhancing RIGI-dependent immune responses.

Therapeutic significance:

DHX16's involvement in Neuromuscular oculoauditory syndrome, a disorder with a broad spectrum of symptoms, highlights its potential as a target for therapeutic intervention. Understanding the role of DHX16 could open doors to potential therapeutic strategies.